2016 Neurotech Leaders Forum

October 24-25, 2016

Embassy Suites, San Francisco Airport Waterfront

Tentative Agenda

Day One: Implantable Neuromodulation Devices

The first day of the 2016 event is devoted to the implantable neuromodulation device industry and is targeted particularly at early-stage neurotechnology firms and research professionals contemplating launching a neurotech startup. Conference faculty and industry panelists will offer important insights on technology and market development.

8:00-8:30

Registration and Coffee

8:30-9:15

State of the Neurotechnology Industry: 2016

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occured over the years, the most significant events of the last year, and challenges confronting the industry in years ahead.
9:15-10:00

Keynote Address

Doug Weber, Ph.D., Program Manager, DARPA Biological Technologies Office
10:00-10:30

Refreshment Break, Sponsored by Cirtec Medical

10:30-11:15

Neurotech Industry Growth: The Global Perspective

Jennifer French, Senior Editor, Neurotech Reports, Moderator
Jason Richey, President, LivaNova Neuromodulation
Andy Jane, Partner, Talu Ventures
Jeremy Koff, Principal, Colibri Partners
In this session, we explore the international market for neurotechnology devices, and examine regulatory, reimbursement, and market factors in markets such as Europe, China, and Australia.
11:15-12:00

Funding Sources for Neurotech Startups

James Cavuoto, Editor, Neurotech Reports, Moderator
Nick Langhals, Ph.D., Neural Engineering Program Director, NIH
Kevin Wasserstein, Founder & CEO, Neurotechnology Innovations Translator
Imran Eba, Partner, Action Potential Venture Capital
Howard Leonhardt, Founder & Chairman, Cal-X Crowdfund Connect
In this session, we'll take a look at new funding opportunities for neurotech startups offered by both government-funded initiatives and venture capital funds. Represenatives from government agencies, strategic players, and VC firms will each offer their unique perspective.
12:00-1:30

Luncheon, Sponsored by Micro Systems Technologies

Presentation of 2016 Gold Electrode Awards
1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Milton Morris, Ph.D., President and CEO, NeuSpera Medical Inc.
Roy Katz, Vice President, Business Development, BlueWind Medical
Brian Blischak, President, Nexeon MedSystems, Inc.
Jeff Hendricks, Ph.D., CEO, Biotectix,
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

Expanding Alternatives in Neurostimulation

Jennifer French, Executive Director, Neurotech Network, Moderator
Joe Pancrazio, Ph.D., Professor of Bioengineering, University of Texas, Dallas
Jeff Kramer, Ph.D., Vice-President and Fellow, Research, St. Jude Medical Neuromodulation
Heather Dunn, Senior Director of Technology, Cirtec Medical Systems
In this session, we'll look at the myriad forms of therapies that neuromodulation device manufacturers are offering to patients and clinicians. We'll discuss the market potential for alternatives such as burst stimulation, DRG stimulation, parasthesia-free stimulation, peripheral nerve stimulation, and RF injectable stimulation.
4:15-5:00

New Opportunities for Brain Devices

James Cavuoto, Editor, Neurotech Reports, Moderator
Stephen Carcieri, Ph.D., Fellow Research Scientist, Boston Scientific Neuromodulation
Colin Kealey, M.D., Chief Medical Officer, NS Vascular
Daniel DiLorenzo, M.D., Ph.D., Neurosurgeon, Rush University Medical Center
In this session, we look at new applications of deep brain stimulation and other implantable neurotech devices. We'll also look at technology advances in leads, stimulation waveforms, targeting, and implantation. We'll also explore progress in understanding the mechanisms of action of new therapies.
5:00-7:00

Cocktail Reception, Sponsored by Stellar Technologies

 
 

 

Day Two: New Frontiers for Neurotechnology

The second day of the conference is devoted to new directions in the neurotechnology industry, including bioelectronic medicine, consumer and noninvasive neurotech devices, and novel neurosensing systems. The sessions offer an exclusive forum for executives and entrepreneurs to interact with investors, technologists, and potential partners who are working to expand the neurotech industry into new areas.

8:00:8:30

Registration and Coffee

8:30-8:45

Introduction: New Frontiers in Neurotechnology

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Reports editor James Cavuoto provides an overview of new neurotech markets, including consumer products, noninvasive stimulation systems, and digital health devices.
8:45-9:15

Keynote Address

Adam Roth, Ph.D., Director of Business Development, GSK/Galvani Bioelectronics
9:15-10:00

New Strategies for Neurorehabilitation

Jennifer French, Senior Editor, Neurotech Reports, Moderator
Mark Chamberlain, COO, Alfred Mann Foundation
Frank McEachern, CEO, MicroTransponder Inc.
Andy Cornwell, Ph.D., Director of Industrial and Strategic Collaborations, Cleveland FES Center
In this session, we'll explore several new approaches to neurorehabilitation using noninvasive brain stimulation. We'll look at applications in stroke therapy, cognitive and motor performance, and traumatic brain injury
10:00-10:30

Coffee Break, Sponsored by Cirtec Medical

10:30-11:15

Bioelectronic Medicine Emerges

Margot Puerta, Editor, Bioelectronic Medicine, Moderator
Jack Judy, Ph.D., Director, Nanoscience Institute for Medical and Engineering Technology, University of Florida
Leon Ekchian, Ph.D., President and CEO, NeuroSigma, Inc.
In this session, we'll look at the growing market for bioelectronic medicine, including applications in cardiovascular neuromodulation, hypertension, and other systemic disorders.
11:15-12:00

Neurotech Meets Digital Health: The Investment Outlook

James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Roger Quy, Partner, Technology Partners
Juan-Pablo-Mas, Partner, Action Potential Venture Capital
John Scull, Managing Director, Southern Cross Venture Partners
In this session, we'll explore the investment outlook for noninvasive neurostimulation and neurosesning systems for both consumer and healthcare applications. We'll hear from venture capital professionals and we'll examine the different routes to profitability and routes to exit for neurotech startups.
12:00-1:30

Luncheon, Sponsored by Micro Systems Technologies

1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Chris Czura, Ph.D., Chief Scientific Office, Sanguistat Inc.
Howard Leonhardt, Chairman and CEO, CerebraCell
Andrew Grosser, Founder, Do by Thinking
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

Brain-Sensing: Consumer and Healthcare Markets

Jennifer French, Senior Editor and Associate Publisher, Neurotech Reports, Moderator
Gaurav Sharma, Ph.D., Principal Research Scientist, Battelle
Marcus Gerhardt, Co-Founder, Blackrock Microsystems
Steve Miller, Ph.D., Chief Scientific Officer, Platypus Institute
In this session, we'll look at the market for brain-computer interfaces and brain analysis systems in both consumer-grade and healthcare categories. We'll discuss the hardware and software features that differentiate the product segments and look for the applications that will make a difference in growing the market.
4:15-5:00

Drugs vs. Devices: A New Paradigm Emerges

Alison Fenney, Ph.D., Director, Industry Alliances, Neurotechnology Industry Organization, Moderator
Chad Bouton, Vice President, Engineering and Advanced Technology, Feinstein Institute for Medical Research
Imran Eba, Partner, Action Potential Venture Capital
In this closing session, we'll examine the changing status of neurotech device therapies vis a vis pharmaceutical aproaches to treating neurological diseases and disorders. We'll look at the role pharmaceutical firms are playing in the growth of bioelectronic medicine and we'll consider neuromodulation therapies that are being called upon earlier in the disease progression.
5:00-7:00

Cocktail Reception, Sponsored by Stellar Technologies

 
 

 

site design by shalatdesign | shalat.com